Introduction: The purpose of this abstract is to report on the application of a triple unified-modality for parenchymal hypertrophy (TRIUMPH) for patients with extensive liver colorectal metastasis. This includes transarterial radioembolization (TARE), portal vein embolization (PVE) and hepatic vein embolization (HVE). Methods: Four patients underwent TRIUMPH between March and August 2020. Results: Patients had a median age of 59 years (45-66) and received 7.5 cycles of chemotherapy (7-16). Time between diagnosis and TARE was of 140.5 days (87.5-199.75), between TARE and PVE of 30.5 days (26.25-91), between PVE and HVE of 1 day (1-74.25, figure 1). The functional liver remnant underwent a relative growth of 100.9 ± 28.4%, with a kinetic rate of 3.3 ± 1.7% per week and an increase in the FLR to 971.5 ± 457ml. All patients underwent successful open extended right hepatectomies with length of stay of 4 days (3-5), and no severe complications (Clavien-Dindo of 0-2). Pathological response was partial in two patients and near complete and complete in the other two. Discussion: This is a promising minimally invasive approach to induce maximal parenchymal hypertrophy and ultimately provide patients with a chance for surgical cure. Even though multiple series have reported ALPPS to be successful in causing liver remnant hypertrophy, it is known to have high morbidity. TRIUMPH holds the advantage of providing local tumor control and contralateral liver hypertrophy in a minimally invasive fashion. Conclusion: The review of these four cases shows the feasibility of what the authors call TRIUMPH in rescuing patients with extensive liver metastasis.